Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro and In Vivo Efficacy of NITD-916 against Mycobacterium fortuitum

15 Mar 2023

Abstract excerpt

Mycobacterium fortuitum represents one of the most clinically relevant rapid-growing mycobacterial species. Treatments are complex due to antibiotic resistance and to severe side effects of effective drugs, prolonged time of treatment, and co-infection with other pathogens.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Mycology
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36920188
DOI: 10.1128/aac.01607-22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro and In Vivo Efficacy of NITD-916 against Mycobacterium fortuitumPMID 36920188Read ↗

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosisSemantic proximity Read ↗

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice modelsSemantic proximity Read ↗

<i>In Vitro</i> efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Inhibition of Glutamine Synthetase: A Potential Drug Target in Mycobacterium tuberculosisSemantic proximity Read ↗

In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous MycobacteriaSemantic proximity Read ↗

In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In VivoSemantic proximity Read ↗

In Vitro Efficacy Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Rapid Growing Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro StudySemantic proximity Read ↗

Dictyosteliumdiscoideum–Mycobacterium marinum infection model: a powerful high-throughput screening platform for anti-infective compoundsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.